Positron emission tomography (PET) study with (11C) flumazenil to determine central GABAA receptor occupancy of AZD6280 - PET

Study identifier:D0850C00011

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open label positron emission tomography (PET) study with (11C)flumazenil to determine central GABAA receptor occupancy of AZD6280 after oral administration to healthy volunteers

Medical condition

Anxiety

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD6280, (11C) flumazenil

Sex

Male

Actual Enrollment

Study type

Interventional

Age

20 Years - 45 Years

Date

Study Start Date: 01 Feb 2008

Primary Completion Date: 01 Sept 2008

Study Completion Date: 01 Sept 2008

Study design

Allocation: Non-randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2008 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

Location

Research Site

Stockholm, Sweden

Arms	Assigned Interventions
Experimental: 1	Drug: AZD6280 Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects. Drug: (11C) flumazenil Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)

"There is no result for the study"

Documents available

Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information

1-800-236-9933

information.center@astrazeneca.com

Investigators

Principal Investigator

Bo Fransson

AstraZeneca Clinical Pharmacology Unit, Stockholm, Sweden